Press releases

Oncopeptides receives formal approval from Norwegian authorities to initiate Window-of-Opportunity study in glioblastoma

COMy: New clinical and real-world evidence for Pepaxti demonstrating strong data and expanded positioning

Oncopeptides publishes Q1 report 2026

Oncopeptides intends to submit type II variation to expand Pepaxti label to include third line treatment

Invitation to presentation of the Q1 report 2026

Oncopeptides publishes the 2025 Annual Report

Annual General Meeting in Oncopeptides

Preclinical data on novel NK-Cell engager to be presented at the AACR Annual Meeting 2026

Number of shares and votes in Oncopeptides

Outcome in Oncopeptides’ rights issue

Oncopeptides initiates MARINA study to strengthen real-world evidence for Pepaxti in Germany

European Journal of Haematology: Real-World Data reinforces Pepaxti’s role in treatment sequencing for multiple myeloma